mass spectrometry is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Last reviewed on 2026-08-01. Where a claim depends on a specific study, the study is described rather than over-claimed.
Research interest in AOD-9604 often focuses on whether it can influence lipid metabolism without the growth-promoting or glucose-related effects of full-length hGH. This question remains unresolved, and findings depend on model, dose, and measurement method. Some reviews treat the peptide as a historical obesity candidate rather than an active therapeutic. Others cite it in discussions of peptide fragments, metabolic signaling, and performance-enhancing substances. Clear conclusions are limited by the small number of rigorous, independent human studies.
AOD-9604 has been investigated primarily as a potential treatment for obesity and related metabolic conditions. Early laboratory work examined its effects on fat cells, and later studies moved into animal models and human clinical trials. Some trials reportedly reached Phase II, but the program did not lead to an approved medicine. Published summaries often note that weight-loss results were modest or inconsistent. The full trial data are not all publicly available in detail.
In laboratory settings, AOD-9604 is commonly supplied as a lyophilized powder and stored cold to limit degradation. Reconstituted solutions are typically kept refrigerated or frozen, depending on the buffer and concentration, and protected from repeated freeze-thaw cycles. Stability can be influenced by pH, temperature, and the presence of proteases. Purity is usually assessed by high-performance liquid chromatography and mass spectrometry. These practices support reproducibility, but they do not imply safety or efficacy for any human use.
Regulatory status: AOD-9604 is not approved as a therapeutic drug in the United States, European Union, or other major markets. It is listed by the World Anti-Doping Agency as a prohibited substance in sport, specifically under growth hormone fragments. Many jurisdictions restrict its sale for human consumption. Products marketed online may not meet pharmaceutical quality standards. The legal status varies by country and often depends on whether the material is presented as a research chemical, supplement, or drug.
Detection and characterization of AOD-9604 in research and anti-doping settings typically rely on mass spectrometry coupled with liquid chromatography. These methods can identify the peptide by its mass and fragmentation pattern. Immunoassays may also be used in some screening contexts, but they can cross-react with related peptides. Because the molecule is small and may be present at low concentrations, sample preparation and method validation are important. Confirmatory analysis usually requires comparison with a certified reference standard.
| Property | Value | Notes |
|---|---|---|
| Primary research area | Obesity and metabolic regulation | Studied in cell, animal, and human models |
| Highest reported trial phase | Phase II | Public summaries describe mixed results |
| Common route in trials | Subcutaneous injection | Typical for peptide therapeutics |
| Regulatory example | 2013 Australian anti-doping review | Classification was debated at the time |
| Approval status | Not approved as a human medicine | Status can change by jurisdiction |
Identity and purity are commonly checked with reversed-phase high-performance liquid chromatography and mass spectrometry. RP-HPLC separates the peptide from related impurities and can estimate purity by peak area. Mass spectrometry confirms molecular mass and helps detect sequence variants or truncations. Some laboratories use amino acid analysis or peptide mapping for additional characterization. No single method proves biological activity; these techniques establish chemical identity and purity only. They also require suitable reference standards for confident comparison.
Commercial AOD-9604 may vary in purity, counterion content, and residual moisture. Certificates of analysis often report HPLC purity, mass confirmation, and appearance, but testing methods differ between suppliers. Independent verification is sometimes used because labeled content may not match actual peptide amount. Stability under different pH and temperature conditions is not fully standardized across studies. Researchers generally treat lyophilized material as the reference form for weighing and reconstitution. Moisture content can affect accurate mass measurement.
AOD-9604 is typically supplied as a lyophilized white to off-white powder. In this form, it is relatively stable when kept cool, dry, and protected from light. Common storage recommendations place it at −20 °C or below for long-term retention. Reconstituted solutions are less stable and are often kept at 2–8 °C for short periods. Freeze-thaw cycles should be minimized because they can promote aggregation or loss of peptide content. Vials are usually sealed under inert gas to reduce oxidation.
Regulatory status varies by country. In the United States, AOD-9604 is not approved as a prescription drug. It is sometimes sold as a research chemical or dietary supplement, though such marketing may fall outside legal frameworks. The World Anti-Doping Agency prohibits its use in sport. Researchers must obtain it through legitimate suppliers and follow institutional rules. Its legal classification continues to evolve as authorities increasingly assess peptide products more broadly.
AOD-9604 is a synthetic peptide whose sequence matches the C-terminal fragment of human growth hormone, specifically residues 176 through 191. This region differs from the full hormone in its receptor interactions. The peptide is not a growth hormone secretagogue and does not bind the growth hormone receptor in the same manner. Researchers have examined it for effects on lipid metabolism, but its exact pharmacological profile remains an active area of study.
Clinical development of AOD-9604 included trials in people with obesity. Reports from early-phase and mid-phase studies described modest or inconsistent changes in body weight. A phase IIb program did not meet its primary endpoint, and the compound was not approved for medical use. Differences in formulation, delivery route, and participant characteristics may explain some of the variation. Later investigations explored whether the peptide might have effects in other tissues, including cartilage.
Regulatory treatment of AOD-9604 is shaped by its classification as a peptide hormone. The World Anti-Doping Agency lists it as a prohibited substance, and many national anti-doping organizations adopt that list. It does not hold approval as a prescription medicine in the United States, the European Union, or other major markets. Products sold online are frequently labeled for research use only and may not undergo independent quality testing. Import and possession rules differ by country, so legal status depends on local law.
Diampromide is an opioid analgesic from the ampromide family of drugs, related to other drugs such as propiram and phenampromide. It was invented in the 1960s by American Cyanamid, and can be described as a ring-opened analogue of fentanyl. Diampromide produces similar effects to other opioids, including analgesia, sedation, dizziness and nausea, and is around the same potency as morphine. Diampromide is in Schedule I of the Controlled Substances Act 1970 of the United States as a Narcotic with ACSCN 9615 with a zero aggregate manufacturing quota as of 2014. It is listed under the Single Convention for the Control of Narcotic Substances 1961 and is controlled in most countries in the same fashion as is morphine.
== Related conditions == Disorders that are clinically similar are konzo and Lytico-bodig disease. Konzo means "tied legs" in the Yaka language, and is common in some African people in central and eastern parts of the continent who are consuming diets poor in protein. The possible molecule causing this problem is thiocyanate, which stimulates AMPA receptors.
Morris Carstairs, in a report on culture and personality study, stated that Indian men who are seemingly healthy are preoccupied with real or imagined spermatorrhea, with the belief that semen is not easily formed and "it takes 40 days, and 40 drops of blood, to make one drop of semen". He observed that when sexual behaviours are restricted, sexual incontinence follows with resultant guilt. In females, the corresponding fear of loss of sexual fluids is found in anxieties over vaginal discharge (sravam), which is believed to be a cooling body lubricant but whose loss leaves them "overheated and disarticulated, in a state of disease." Anxiety about loss of sexual fluids is caused from a misdiagnosis of sexual guilt, instead of correcting the psyche of a person the focus is shifted onto the substance (semen, sravam), resulting in subsequent pathologization. In Ayurveda, the term generally used for both male semen and female egg cell is Shukra. People with healthy shukra appear stronger and confident, with eyes and skin that seem lustrous. Those who lack higher shukra appear exhausted and lackluster, while also struggling in creative endeavours. Drinking lots of water and proper digestion of highly nourishing foods (milk, ghee, nuts) yield healthy shukra. Charaka states brahmacharya (abstinence), proper diet, and rest/sleep as the three pillars of life.
==== In human fetuses ==== In human embryos and fetuses, ethanol is not metabolized via ADH as ADH enzymes are not yet expressed to any significant quantity in human fetal liver (the induction of ADH only starts after birth, and requires years to reach adult levels). Accordingly, the fetal liver cannot metabolize ethanol or other low molecular weight xenobiotics. In fetuses, ethanol is instead metabolized at much slower rates by different enzymes from the cytochrome P-450 superfamily (CYP), in particular by CYP2E1. The low fetal rate of ethanol clearance is responsible for the important observation that the fetal compartment retains high levels of ethanol long after ethanol has been cleared from the maternal circulation by the adult ADH activity in the maternal liver. CYP2E1 expression and activity have been detected in various human fetal tissues after the onset of organogenesis (ca 50 days of gestation). Exposure to ethanol is known to promote further induction of this enzyme in fetal and adult tissues. CYP2E1 is a major contributor to the so-called Microsomal Ethanol Oxidizing System (MEOS) and its activity in fetal tissues is thought to contribute significantly to the toxicity of maternal ethanol consumption. In presence of ethanol and oxygen, CYP2E1 is known to release superoxide radicals and induce the oxidation of polyunsaturated fatty acids to toxic aldehyde products like 4-hydroxynonenal (HNE). The concentration of alcohol in breast milk produced during lactation is closely correlated to the individual's blood alcohol content.
==== Health claims ==== The Japanese Ministry of Health, Labor, and Welfare (MHLW) set up the 'Foods for Specified Health Uses' (特定保健用食品; FOSHU) regulatory system in 1991 to individually approve the statements made on food labels concerning the effects of foods on the human body. The regulatory range of FOSHU was later broadened to allow for the certification of capsules and tablets. In 2001, MHLW enacted a new regulatory system, 'Foods with Health Claims' (保健機能食品; FHC), which consists of the existing FOSHU system and the newly established 'Foods with Nutrient Function Claims' (栄養機能表示食品; FNFC), under which claims were approved for any product containing a specified amount per serving of 12 vitamins, including vitamin B6, and two minerals. To make a health claim based on a food's vitamin B6 content, the amount per serving must be in the range of 0.3–25 mg. The allowed claim is: "Vitamin B6 is a nutrient that helps produce energy from protein and helps maintain healthy skin and mucous membranes." In 2010, the European Food Safety Authority (EFSA) published a review of proposed health claims for vitamin B6, disallowing claims for bone, teeth, hair skin and nails, and allowing claims that the vitamin provided for normal homocysteine metabolism, normal energy-yielding metabolism, normal psychological function, reduced tiredness and fatigue, and provided for normal cysteine synthesis. The US Food and Drug Administration (FDA) has several processes for permitting health claims on food and dietary supplement labels.
Sources: en.wikipedia.org
Wilhelm Wien demonstrates that canal rays can be deflected using strong electric and magnetic fields. He shows that the mass-to-charge ratio of the particles have opposite polarity and is much larger compared to the electron. He also realizes that the particle mass is similar to that of the hydrogen particle. 1898 J. J. Thomson measures the mass-to-charge ratio of electrons.
Hemocyanin is homologous to the phenol oxidases (e.g. tyrosinase) since both proteins have histidine residues, called "type 3" copper-binding coordination centers, as do the enzymes tyrosinase and catechol oxidase. In both cases inactive precursors to the enzymes (also called zymogens or proenzymes) must be activated first. This is done by removing the amino acid that blocks the entrance channel to the active site when the proenzyme is not active. There are currently no other known modifications necessary to activate the proenzyme and enable catalytic activity. Conformational differences determine the type of catalytic activity that the hemocyanin is able to perform. Hemocyanin also exhibits phenol oxidase activity, but with slowed kinetics from greater steric bulk at the active site. Partial denaturation actually improves hemocyanin's phenol oxidase activity by providing greater access to the active site.
The acyl azide of a peptide (1) undergoes a Curtius rearrangement in the presence of benzyl alcohol and heat(2) to give a benzyl carbamate (3). The Cbz group of intermediate 3 is removed by hydrogenolysis to give an unsubstituted amide (4) and an aldehyde (5).
Wind direction plays a critical role in shaping the inland extent of X. parietina. Southwesterly winds in the warmer months carry marine aerosols further inland, while easterly storms contribute additional sea salt deposition through precipitation. The influence of these aerosols is evident in Maine cemeteries: X. parietina is more frequent in open cemeteries exposed to prevailing winds, compared to wooded cemeteries, which block or capture airborne sea salts, and have significantly lower frequencies of the lichen. In recent decades, inland populations of X. parietina have been discovered in southern Ontario, suggesting an expansion beyond its traditionally coastal range. Once considered extirpated from the region, the species was rediscovered growing on trees in several inland locations. This inland occurrence raises questions about whether the lichen has reestablished after a long absence or has persisted undetected for decades. The expansion may be linked to increasing nitrogen deposition from agricultural runoff and air pollution, which create conditions favorable for nitrophilous lichens like X. parietina. Another possible factor in its inland spread is the widespread use of road salt in Ontario over the past 50–70 years. Since X. parietina thrives in salt-rich coastal environments, roadside salt deposition may have provided an artificial habitat, mimicking the chemical conditions of maritime regions.
Sources: en.wikipedia.org
No major medicines regulator appears to have approved AOD-9604 for human therapeutic use. It has been studied in clinical trials, but those programs did not result in a marketed drug.
It became prominent during a 2013 Australian sports investigation that examined whether it was a prohibited growth-hormone-related substance. Subsequent interpretations and list updates have varied, so current rules should be checked directly.
Published summaries generally report limited or inconsistent weight-loss effects, and complete trial data are not widely available. The studies were not sufficient to establish it as an effective obesity treatment.
No major regulatory agency has approved AOD-9604 as a medicine. It is treated as an experimental peptide in research settings. Some countries restrict its sale or import.